Enhanced expression of transferrin receptor 1 contributes to oncogenic signalling by sphingosine kinase 1

Oncogene

Volumn 33, Issue 48, 2014, Pages 5559-5568

  Pham, D H ^a,b   Powell, J A ^a   Gliddon, B L ^a   Moretti, P A B ^a   Tsykin, A ^a,b   Van Der Hoek, M ^c   Kenyon, R ^c   Goodall, G J ^a,b,d   Pitson, S M ^a,b,d  

^a CENTRE FOR CANCER BIOLOGY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c Adelaide Microarray Centre   (Australia)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

DNA microarray; expression profiling; neoplastic transformation; sphingosine kinase; transferrin receptor

Indexed keywords

CD71 ANTIGEN; LEUKOCYTE ANTIGEN; PHOSPHOTRANSFERASE; SMALL INTERFERING RNA; SPHINGOSINE KINASE; TRANSFERRIN RECEPTOR;

ANIMAL; CELL LINE; CELL TRANSFORMATION; DNA MICROARRAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; IMMUNOBLOTTING; METABOLISM; MOUSE; NEOPLASM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOBLOTTING; MICE; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TRANSFERRIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84887938590     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.502     Document Type: Article

References (72)

1. Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci 2011; 36: 97-107.
2. Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 1999; 147: 545-558.
3. Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW et al. An oncogenic role of sphingosine kinase. Curr Biol 2000; 10: 1527-1530.
4. Pitson SM, Powell JA, Bonder CS. Regulation of sphingosine kinase in hematological malignancies and other cancers. Anticancer Agents Med Chem 2011; 11: 799-809.
5. Chan H, Pitson SM. Post-translational regulation of sphingosine kinases. Biochim Biophys Acta 2013; 1831: 147-156.
6. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010; 10: 489-503.
7. Kohno M, Momoi M, Oo ML, Paik JH, Lee YM, Venkataraman K et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol 2006; 26: 7211-7223.
8. Kawamori T, Osta W, Johnson KR, Pettus BJ, Bielawski J, Tanaka T et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 2006; 20: 386-388.
9. Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J et al. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J 2009; 23: 405-414.
10. Ponnusamy S, Selvam SP, Mehrotra S, Kawamori T, Snider AJ, Obeid LM et al. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med 2012; 4: 761-775.
11. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 2005; 65: 11667-11675.
12. Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007; 282: 10922-10934.
13. Pitman MR, Pitson SM. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets 2010; 10: 354-367.
14. Pitson SM, Moretti PA, Zebol JR, Lynn HE, Xia P, Vadas MA et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J 2003; 22: 5491-5500.
15. Pitson SM, Xia P, Leclercq TM, Moretti PA, Zebol JR, Lynn HE et al. Phosphorylation- dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med 2005; 201: 49-54.
16. Strub GM, Maceyka M, Hait NC, Milstien S, Spiegel S. Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 2010; 688: 141-155.
17. Pham DH, Moretti PA, Goodall GJ, Pitson SM. Attenuation of leakiness in doxycycline- inducible expression via incorporation of 3' AU-rich mRNA destabilizing elements. Biotechniques 2008; 45: 155-156, 8, 60 passim.
18. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63: 5962-5969.
19. Pitson SM, Moretti PA, Zebol JR, Xia P, Gamble JR, Vadas MA et al. Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase. J Biol Chem 2000; 275: 33945-33950.
20. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006; 121: 144-158.
21. Habeshaw JA, Lister TA, Stansfeld AG, Greaves MF. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet 1983; 1: 498-501.
22. Ryschich E, Huszty G, Knaebel HP, Hartel M, Buchler MW, Schmidt J. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer 2004; 40: 1418-1422.
23. Das Gupta A, Shah VI. Correlation of transferrin receptor expression with histologic grade and immunophenotype in chronic lymphocytic leukemia and non- Hodgkin's lymphoma. Hematol Pathol 1990; 4: 37-41.
24. Prior R, Reifenberger G, Wechsler W. Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction. Virchows Arch A Pathol Anat Histopathol 1990; 416: 491-496.
25. Wirth GJ, Schandelmaier K, Smith V, Burger AM, Fiebig HH. Microarrays of 41 human tumor cell lines for the characterization of new molecular targets: expression patterns of cathepsin B and the transferrin receptor. Oncology 2006; 71: 86-94.
26. Helpman L, Katz BZ, Safra T, Schreiber L, Levine Z, Nemzer S et al. Systematic antigenic profiling of hematopoietic antigens on ovarian carcinoma cells identifies membrane proteins for targeted therapy development. Am J Obstet Gynecol 2009; 201: 196.e1-196.e7.
27. O'Donnell KA, Yu D, Zeller KI, Kim JW, Racke F, Thomas-Tikhonenko A et al. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol 2006; 26: 2373-2386.
28. Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat 2010; 119: 283-293.
29. Zhou HJ, Wang Z, Li A. Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression. Anticancer Drugs 2008; 19: 247-255.
30. Shen X, Zhu HF, He FR, Xing W, Li L, Liu J et al. An anti-transferrin receptor antibody enhanced the growth inhibitory effects of chemotherapeutic drugs on human non-hematopoietic tumor cells. Int Immunopharmacol 2008; 8: 1813-1820.
31. Callens C, Moura IC, Lepelletier Y, Coulon S, Renand A, Dussiot M et al. Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia 2008; 22: 42-48.
32. Jiang XP, Elliott RL, Head JF. Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas. Anticancer Res 2010; 30: 759-765.
33. van Dam EM, Ten Broeke T, Jansen K, Spijkers P, Stoorvogel W. Endocytosed transferrin receptors recycle via distinct dynamin and phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 2002; 277: 48876-48883.
34. El-Shewy HM, Johnson KR, Lee MH, Jaffa AA, Obeid LM, Luttrell LM. Insulin-like growth factors mediate heterotrimeric G protein-dependent ERK1/2 activation by transactivating sphingosine 1-phosphate receptors. J Biol Chem 2006; 281: 31399-31407.
35. Meyer zu Heringdorf D, Lass H, Kuchar I, Lipinski M, Alemany R, Rumenapp U et al. Stimulation of intracellular sphingosine-1-phosphate production by G-proteincoupled sphingosine-1-phosphate receptors. Eur J Pharmacol 2001; 414: 145-154.
36. Long JS, Fujiwara Y, Edwards J, Tannahill CL, Tigyi G, Pyne S et al. Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J Biol Chem 2010; 285: 35957-35966.
37. Salomone S, Waeber C. Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects. Front Pharmacol 2011; 2: 9.
38. Trowbridge IS, Lopez F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Natl Acad Sci USA 1982; 79: 1175-1179.
39. Trowbridge IS, Shackelford DA. Structure and function of transferrin receptors and their relationship to cell growth. Biochem Soc Symp 1986; 51: 117-129.
40. Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W et al. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 2005; 106: 1808-1816.
41. Jarman KE, Moretti PA, Zebol JR, Pitson SM. Translocation of sphingosine kinase 1 to the plasma membrane is mediated by calcium- and integrin-binding protein 1. J Biol Chem 2010; 285: 483-492.
42. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci 2004; 1012: 1-13.
43. Takeshita A, Watanabe A, Takada Y, Hanazawa S. Selective stimulation by ceramide of the expression of the alpha isoform of retinoic acid and retinoid X receptors in osteoblastic cells. A role of sphingosine 1-phosphate-mediated AP-1 in the ligand-dependent transcriptional activity of these receptors. J Biol Chem 2000; 275: 32220-32226.
44. Okazaki F, Matsunaga N, Okazaki H, Utoguchi N, Suzuki R, Maruyama K et al. Circadian rhythm of transferrin receptor 1 gene expression controlled by c-Myc in colon cancer-bearing mice. Cancer Res 2010; 70: 6238-6246.
45. Bianchi L, Tacchini L, Cairo G. HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res 1999; 27: 4223-4227.
46. Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O. Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res 2008; 68: 8635-8642.
47. Ader I, Malavaud B, Cuvillier O. When the sphingosine kinase 1/sphingosine 1-phosphate pathway meets hypoxia signaling: new targets for cancer therapy. Cancer Res 2009; 69: 3723-3726.
48. Michaud MD, Robitaille GA, Gratton JP, Richard DE. Sphingosine-1-phosphate: a novel nonhypoxic activator of hypoxia-inducible factor-1 in vascular cells. Arterioscler Thromb Vasc Biol 2009; 29: 902-908.
49. Takuwa N, Du W, Kaneko E, Okamoto Y, Yoshioka K, Takuwa Y. Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde. Am J Cancer Res 2011; 1: 460-481.
50. Cattoretti G, Mandelbaum J, Lee N, Chaves AH, Mahler AM, Chadburn A et al. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res 2009; 69: 8686-8692.
51. Li MH, Sanchez T, Milne GL, Morrow JD, Hla T, Ferrer F. S1P/S1P2 signaling induces cyclooxygenase-2 expression in Wilms tumor. J Urol 2009; 181: 1347-1352.
52. Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA et al. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr- Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood 2011; 117: 5941-5952.
53. Young JC, Barral JM, Ulrich Hartl F. More than folding: localized functions of cytosolic chaperones. Trends Biochem Sci 2003; 28: 541-547.
54. Pitson SM, D'Andrea RJ, Vandeleur L, Moretti PA, Xia P, Gamble JR et al. Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes. Biochem J 2000; 350(Pt 2): 429-441.
55. Park HS, Park CH, Choi BR, Lim MS, Heo SH, Kim CH et al. Expression of heat shock protein 105 and 70 in malignant melanoma and benign melanocytic nevi. J Cutan Pathol 2009; 36: 511-516.
56. Jose-Eneriz ES, Roman-Gomez J, Cordeu L, Ballestar E, Garate L, Andreu EJ et al. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia. Br J Haematol 2008; 142: 571-582.
57. Muchemwa FC, Nakatsura T, Fukushima S, Nishimura Y, Kageshita T, Ihn H. Differential expression of heat shock protein 105 in melanoma and melanocytic naevi. Melanoma Res 2008; 18: 166-171.
58. Muchemwa FC, Nakatsura T, Ihn H, Kageshita T. Heat shock protein 105 is overexpressed in squamous cell carcinoma and extramammary Paget disease but not in basal cell carcinoma. Br J Dermatol 2006; 155: 582-585.
59. Huang WJ, Xia LM, Zhu F, Huang B, Zhou C, Zhu HF et al. Transcriptional upregulation of HSP70-2 by HIF-1 in cancer cells in response to hypoxia. Int J Cancer 2009; 124: 298-305.
60. Tran PL, Kim SA, Choi HS, Yoon JH, Ahn SG. Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo. BMC Cancer 2010; 10: 276.
61. Sun J, Liu L, Jiang X, Chen D, Huang Y. Therapeutic effects of radiolabeled 17-allylamino-17-demethoxygeldanamycin on human H460 nonsmall-cell lung carcinoma xenografts in mice. Cancer Biother Radiopharm 2010; 25: 155-164.
62. Hosaka S, Nakatsura T, Tsukamoto H, Hatayama T, Baba H, Nishimura Y. Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitro and in vivo. Cancer Sci 2006; 97: 623-632.
63. Schwock J, Pham NA, Cao MP, Hedley DW. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol 2008; 61: 669-681.
64. Loveridge C, Tonelli F, Leclercq T, Lim KG, Long JS, Berdyshev E et al. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem 2010; 285: 38841-38852.
65. Persons DA, Allay JA, Allay ER, Ashmun RA, Orlic D, Jane SM et al. Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis. Blood 1999; 93: 488-499.
66. Pitman MR, Barr RK, Gliddon BL, Magarey AM, Moretti PA, Pitson SM. A critical role for the protein phosphatase 2A B'alpha regulatory subunit in dephosphorylation of sphingosine kinase 1. Int J Biochem Cell Biol 2011; 43: 342-347.
67. Yang YH, Buckley MJ, Speed TP. Analysis of cDNA microarray images. Brief Bioinform 2001; 2: 341-349.
68. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W (eds) Bioinformatics and Computational Biology Solutions using R and Bioconductor. Springer: New York, NY, USA, 2005, pp 397-420.
69. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods 2003; 31: 265-273.
70. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (e-pub ahead of print 12 February 2014; doi:10.2202/1544-6115.1027).
71. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289-300.
72. Pitman MR, Pham DH, Pitson SM. Isoform-selective assays for sphingosine kinase activity. Methods Mol Biol 2012; 874: 21-31.